ReHand Launches a €300,000 Crowdfunding Round

ReHand, an Andalusian startup in the health sector, has launched an investment round to raise €300,000 that will allow it to take another leap in its growth in Europe and Latin America as a company specializing in digitizing the rehabilitation of trauma and bone, and muscle or neurological injuries. A crowdfunding model has been chosen for this round. Currently, with 37 days left to close the round, 65% of the expected capital has been covered by 77 investors.

The investment round that is underway, with minimum contributions of €500, is led by Capital Cell with the aim of scaling the optimal results achieved in Spain to other countries and go beyond the nearly 100 clinics and hospitals that they have as clients, with special emphasis on markets that regulate these digital tools such as Germany.

Founded in Seville in 2016 by Jesús Blanquero, Alejandro Suero, and José Manuel López, they began to stand out being known as Healthinn, collaborating closely with the Andalusian Public Health System. After its embryonic stage in Andalucía Open Future, they have accelerated its development thanks to reference entities such as the European Institute of Innovation and Technology (EIT Health), having its headquarters for the last three years in the Center for Advanced Business Resources (CREA) of the City of Seville.

If you want to read more details about ReHand and find the most important financial news of the day, download for free our companion app. The Born2Invest mobile app, available for both Android and iOS devices, brings you the most important market updates for you to stay informed.

Engineering and clinic

Jesús Blanquero, CEO of ReHand, explains that the company “was born from clinical practice because we observed that there was a wide margin for improvement in the care processes of rehabilitation services, which could be addressed through mobile technologies. From there, we created a research team and brought together complementary profiles from the clinical and computer engineering fields. The room for improvement was so large that we had to start somewhere. We decided to focus initially on wrist, hand, and finger rehabilitation, because of its frequency, its impact on the daily activities of a large number of people, and to demonstrate that we could have an impact on reducing healthcare costs.”

ReHand became the first digital solution via tablet for the rehabilitation of wrist, hand, and fingers, which account for 29% of the injuries that reach hospital emergency departments. In the European Union countries as a whole, there are around 7 million injuries in this segment every year. Blanquero recalls that “the first funds to support our research and development were obtained through the Ministry of Health of the Andalusian Regional Government.

This made it possible to carry out a multicenter clinical trial with more than 600 patients, in which reference hospitals such as the Virgen Macarena and Virgen del Rocío Hospitals participated. The quality of the results was accredited in publications in international scientific journals.

__

(Featured image by andreas160578 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista.es, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.